Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call set for July 30, 2020, at 5pm ET to discuss its second-quarter 2020 financial results and provide corporate updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call set for July 30, 2020, at 5pm ET to discuss its second-quarter 2020 financial results and provide corporate updates. The call will be accessible via phone and through a live webcast on the company’s website. Ultragenyx is dedicated to developing treatments for rare genetic diseases, featuring a diverse portfolio of approved therapies and product candidates aimed at high unmet medical needs. The management team emphasizes efficient drug development to deliver therapies urgently.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -1.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 30, 2020 at 5pm ET to discuss second quarter 2020 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 1808389. The replay of the call will be available for one year.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at:
www.ultragenyx.com
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.